Trial Profile
A trial to compare piperacillin/tazobactam and cefepime for the treatment of AmpC-inducible enterobacteriaceae infections
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 May 2016
Price :
$35
*
At a glance
- Drugs Cefepime (Primary) ; Piperacillin/tazobactam (Primary)
- Indications Enterobacteriaceae infections
- Focus Adverse reactions; Therapeutic Use
- 10 May 2016 New trial record
- 12 Apr 2016 Results presented at the 26th European Congress of Clinical Microbiology and Infectious Diseases